Close Menu

Regeneron

A Regeneron-led team identified four variants that affect LDL cholesterol levels and are much more prevalent among Southwestern American Indians.

Regeneron Pharmaceuticals is among the new investors, as the bioinformatics company continues to scale up its multiomics platform to meet growing demand.

Regeneron will sequence and annotate 450,000 exomes and pair the data with UCHealth patient records to advance drug discovery and precision medicine.

Regeneron is covering the cost of the sequencing and genotyping, and both partners will have access to the data for research purposes.

A team compared expression in duodenum samples from active celiac cases, cases in remission, and unaffected controls, identifying active disease-related expression shifts.

The project dovetails with a separate effort to sequence the whole exomes of the samples, the first 50,000 of which became available to researchers this month.

In PNAS this week: single-cell analysis of blood cells from malaria mosquito vector, genes contributing to high yield in rice, and more.

In analyses of multiple traits and diseases, investigators uncovered loss-of-function or truncating changes with apparent protective effects.

Using exomes and linked electronic health records, the team uncovered a loss-of-function variant associated with decreased risk of liver disease and cirrhosis.

The partners will sequence Indian populations in order to uncover the role of genetic variation in human biology and disease.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.